FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2097506722> ?p ?o ?g. }

• W2097506722 endingPage "1863" @default.
• W2097506722 startingPage "1858" @default.
• W2097506722 abstract "<h3>Abstract</h3> <b>Objective:</b> To determine the relative risk of hip fracture associated with postmenopausal hormone replacement therapy including the effect of duration and recency of treatment, the addition of progestins, route of administration, and dose. <b>Design:</b> Population based case-control study. <b>Setting:</b> Six counties in Sweden. <b>Subjects:</b> 1327 women aged 50-81 years with hip fracture and 3262 randomly selected controls. <b>Main outcome measure:</b> Use of hormone replacement therapy. <b>Results:</b> Compared with women who had never used hormone replacement therapy, current users had an odds ratio of 0.35 (95 % confidence interval 0.24 to 0.53) for hip fracture and former users had an odds ratio of 0.76 (0.57 to 1.01). For every year of therapy, the overall risk decreased by 6% (3% to 9%): 4% (1% to 8%) for regimens without progestin and 11% (6% to 16%) for those with progestin. Last use between one and five years previously, with a duration of use more than five years, was associated with an odds ratio of 0.27 (0.08 to 0.94). After five years without hormone replacement therapy the protective effect was substantially diminished (7% to 48%). With current use, an initiation of therapy nine or more years after the menopause gave equally strong reduction in risk for hip fracture as an earlier start. Oestrogen treatment with skin patches gave similar risk estimates as oral regimens. <b>Conclusions:</b> Recent use of hormone replacement therapy is required for optimum fracture protection, but therapy can be started several years after the menopause. The protective effect increases with duration of use, and an oestrogen-sparing effect is achieved when progestins are included in the regimen. <h3>Key messages</h3> Hormone replacement therapy should be continued for long periods for optimal protection of hip fracture No overall substantial hip fracture protection remains after five years without hormone replacement therapy Therapy can be initiated several years after menopause without loss of fracture protection Oral or transdermal therapy are equally effective in reducing the risk of hip fracture The addition of progestins permits lower doses of oestrogens" @default.
• W2097506722 created "2016-06-24" @default.
• W2097506722 creator A5004994561 @default.
• W2097506722 creator A5014403177 @default.
• W2097506722 creator A5020208883 @default.
• W2097506722 creator A5036373801 @default.
• W2097506722 creator A5055209234 @default.
• W2097506722 creator A5057664322 @default.
• W2097506722 creator A5073182706 @default.
• W2097506722 creator A5082190944 @default.
• W2097506722 date "1998-06-20" @default.
• W2097506722 modified "2023-10-18" @default.
• W2097506722 title "Hormone replacement therapy and risk of hip fracture: population based case-control study" @default.
• W2097506722 cites W2002535656 @default.
• W2097506722 cites W2020457463 @default.
• W2097506722 cites W2023639601 @default.
• W2097506722 cites W2031570803 @default.
• W2097506722 cites W2031984617 @default.
• W2097506722 cites W2033579283 @default.
• W2097506722 cites W2035593552 @default.
• W2097506722 cites W2039415315 @default.
• W2097506722 cites W2042949087 @default.
• W2097506722 cites W2046983302 @default.
• W2097506722 cites W2047553189 @default.
• W2097506722 cites W2053593143 @default.
• W2097506722 cites W2063031738 @default.
• W2097506722 cites W2073829233 @default.
• W2097506722 cites W2078060134 @default.
• W2097506722 cites W2078406992 @default.
• W2097506722 cites W2090962689 @default.
• W2097506722 cites W2092374375 @default.
• W2097506722 cites W2093749501 @default.
• W2097506722 cites W2141006169 @default.
• W2097506722 cites W2154697918 @default.
• W2097506722 cites W228695256 @default.
• W2097506722 cites W2339861034 @default.
• W2097506722 cites W2340559658 @default.
• W2097506722 cites W4252543199 @default.
• W2097506722 cites W4255513594 @default.
• W2097506722 cites W44375275 @default.
• W2097506722 doi "https://doi.org/10.1136/bmj.316.7148.1858" @default.
• W2097506722 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/28583" @default.
• W2097506722 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9632404" @default.
• W2097506722 hasPublicationYear "1998" @default.
• W2097506722 type Work @default.
• W2097506722 sameAs 2097506722 @default.
• W2097506722 citedByCount "237" @default.
• W2097506722 countsByYear W20975067222012 @default.
• W2097506722 countsByYear W20975067222013 @default.
• W2097506722 countsByYear W20975067222014 @default.
• W2097506722 countsByYear W20975067222015 @default.
• W2097506722 countsByYear W20975067222016 @default.
• W2097506722 countsByYear W20975067222017 @default.
• W2097506722 countsByYear W20975067222018 @default.
• W2097506722 countsByYear W20975067222019 @default.
• W2097506722 countsByYear W20975067222020 @default.
• W2097506722 countsByYear W20975067222021 @default.
• W2097506722 countsByYear W20975067222022 @default.
• W2097506722 countsByYear W20975067222023 @default.
• W2097506722 crossrefType "journal-article" @default.
• W2097506722 hasAuthorship W2097506722A5004994561 @default.
• W2097506722 hasAuthorship W2097506722A5014403177 @default.
• W2097506722 hasAuthorship W2097506722A5020208883 @default.
• W2097506722 hasAuthorship W2097506722A5036373801 @default.
• W2097506722 hasAuthorship W2097506722A5055209234 @default.
• W2097506722 hasAuthorship W2097506722A5057664322 @default.
• W2097506722 hasAuthorship W2097506722A5073182706 @default.
• W2097506722 hasAuthorship W2097506722A5082190944 @default.
• W2097506722 hasBestOaLocation W20975067221 @default.
• W2097506722 hasConcept C121608353 @default.
• W2097506722 hasConcept C126322002 @default.
• W2097506722 hasConcept C141071460 @default.
• W2097506722 hasConcept C156957248 @default.
• W2097506722 hasConcept C2776348710 @default.
• W2097506722 hasConcept C2776541429 @default.
• W2097506722 hasConcept C2776607906 @default.
• W2097506722 hasConcept C2778562196 @default.
• W2097506722 hasConcept C2778885795 @default.
• W2097506722 hasConcept C2779279991 @default.
• W2097506722 hasConcept C2780159708 @default.
• W2097506722 hasConcept C2780275930 @default.
• W2097506722 hasConcept C2908647359 @default.
• W2097506722 hasConcept C44249647 @default.
• W2097506722 hasConcept C530470458 @default.
• W2097506722 hasConcept C68312169 @default.
• W2097506722 hasConcept C71315377 @default.
• W2097506722 hasConcept C71924100 @default.
• W2097506722 hasConcept C82789193 @default.
• W2097506722 hasConcept C99454951 @default.
• W2097506722 hasConceptScore W2097506722C121608353 @default.
• W2097506722 hasConceptScore W2097506722C126322002 @default.
• W2097506722 hasConceptScore W2097506722C141071460 @default.
• W2097506722 hasConceptScore W2097506722C156957248 @default.
• W2097506722 hasConceptScore W2097506722C2776348710 @default.
• W2097506722 hasConceptScore W2097506722C2776541429 @default.
• W2097506722 hasConceptScore W2097506722C2776607906 @default.
• W2097506722 hasConceptScore W2097506722C2778562196 @default.
• W2097506722 hasConceptScore W2097506722C2778885795 @default.

• next